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1398Abstract: Acceptance and commitment therapy (ACT) is a developing approach for chronic pain. The
current study was designed to pilot test a brief, widely inclusive, local access format of ACT in a UK pri-
mary care setting. Seventy-three participants (68.5% women) were randomized to either ACTor treat-
ment as usual (TAU). Many of the participants were aged 65 years or older (27.6%), were diagnosed
withfibromyalgia (30.2%)anddepression (40.3%),andhad longstandingpain (median=10years). Stan-
dard clinical outcome measures included disability, depression, physical functioning, emotional func-
tioning, and rated improvement. Process measures included pain-related and general psychological
acceptance. The recruitment target was met within 6 months, and 72.9% of those allocated to ACT
completed treatment. Immediately post treatment, relative to TAU, participants in ACT demonstrated
lower depression and higher ratings of overall improvement. At a 3-month follow-up, again relative
to TAU, those inACTdemonstrated lowerdisability, less depression, and significantly higher pain accep-
tance; d = .58, .59, and .64, respectively. Analyses based on intention-to-treat and on treatment ‘‘com-
pleters,’’ perhaps predictably, revealed more sobering and more encouraging results, respectively. A
larger trial of ACT delivered in primary care, in the format employed here, appears feasible with some
recommended adjustments in the methods used here (Trial registration: ISRCTN49827391).
Perspective: This article presents a pilot randomized controlled trial of ACT for chronic pain in a
primary care setting in the United Kingdom. Both positive clinical outcomes and ways to improve
future trials are reported.
ª 2013 by the American Pain Society. Published by Elsevier Inc. All rights reserved
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pain, including cognitive behavioral therapy (CBT),
have been the predominant psychological treat-
ment for most of the past 30 years.12,21 These
approaches, as the name implies, focus on creating
cognitive and behavioral change to help people who
have chronic pain to suffer less, function better, and
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.doi.org/10.1016/j.jpain.2013.06.011evidence for CBT for chronic pain is supportive.4,22
However, the benefits of CBT for chronic pain are not
as large and general as they could or should be,
including only small effects on disability.37 Some
improvement in the CBT approach may be needed.
It is has been suggested that researchers stop testing
package treatments that essentially attempt to treat
the many problems of chronic pain with many methods
in combination.4 There are calls to focus on therapeutic
mechanisms, or processes, and moderators, the answers
to the questions of how treatment works and for
whom.4,15,23,37 There are also calls for approaches that
include more comprehensive and integrative
theoretical modes.9,11
Acceptance and commitment therapy (ACT)7 is a form
of CBT that may help advance the field of chronic pain
management. ACT is not a package-based approach—it
is process focused, primarily including a therapeutic
McCracken, Sato, and Taylor The Journal of Pain 1399process called psychological flexibility. Psychological
flexibility is the ability to either engage in a behavior
pattern or change a behavior pattern depending on
one’s goals and what the situation affords, in a context
of interacting cognitive and direct, noncognitive, influ-
ences on behavior.6 Psychological flexibility includes 6
constituent processes: acceptance, present-focused
awareness, values, cognitive defusion, self-as-observer,
and committed action. ACT is comprehensive, encom-
passing both healthy and unhealthy psychological pro-
cesses; integrative; and theoretically based. It focuses
on behavior change and on any manipulable influences
that can be applied in changing behavior, incorporating
influences based in emotional experiences, thoughts, be-
liefs, and social context. ACT is based on an extension of
operant theory that includes a model of cognition and
cognitive regulation of behavior, called relational frame
theory, and on a philosophy of science called functional
contextualism.8
There are now at least 5 randomized controlled clinical
trials (RCTs) of ACTrelated to chronic pain that support its
efficacy.2,27,34-36 A wide variety of formats of delivery
have been tested but none of these were specifically
designed for high-efficiency screening and wide inclu-
sion, for recruitment and delivery in primary care in the
UK, over a short time frame, and in a group treatment
context. The only ACT-based treatment tested within
theUKNationalHealth Service is ahigh-intensity interdis-
ciplinary model, including more than 90 hours of treat-
ment time, delivered in a specialty hospital setting.20
The purpose of this study was to pilot test a brief
version of ACT for chronic pain in a primary care setting,
in a small RCT. The treatment tested here was designed
to be broadly accessible, with highly inclusive recruit-
ment criteria, and efficient to deliver, including just 4 ses-
sions over 2 weeks.18 An array of potential primary
outcome and treatment process variables were collected,
including disability, depression, physical functioning,
pain, and acceptance, to determine a best primary
outcome and process measures for a larger trial of the
same treatment. Specific power calculations were not a
part of the planning of the study; hence, the primary
focus was not on testing predictions for specific, signifi-
cant outcome effects. The overall objective here was to
test key trial methods to plan for a larger study, to gather
data for future power calculations, and to consider ways
to enhance the treatment or themethods for studying it.Method
Trial Design
This study included a randomized pilot trial of group
treatment for people with chronic pain recruited from
general practice. After baseline assessment, participants
were randomized to ACT plus treatment-as-usual (TAU)
or TAUalone (1:1) basedon computer-generated random
numbers. The allocationwas not concealed from the par-
ticipants, treatment providers, or the researcher; howev-
er, assessment and data entry were conducted blind to
allocation. Posttreatment assessment was conductedwithin 2 weeks of treatment completion (with parallel
assessment of those in the TAU group) and at a 3-month
follow-up. Sample size was determined on a plan to re-
cruit between 8 and 12 participants for each of 3 ACT
groups. A total sample of 60 participants was the target.
This study was approved by the regional research ethics
committee (reference: 09/H0107/99) and National Health
Service Research and Development committee at the
Royal National Hospital for Rheumatic Diseases in Bath.Recruitment
Participants for this study were recruited from general
medical practices in the southwest of England. These
practices were recruited through the regional Primary
Care Research Network. The practices expressing interest
included 119,000 registered patients, and the individual
practice list sizes ranged from 5,300 to 13,000. Recruit-
ment was conducted over a period of 2 months in each
of 3 separate areas in the southwest primarily during
the first quarter of 2012.
Potential participants at each of the practices were
identified through record searches applying the inclu-
sion criteria. Inclusion in the study required persistent
pain of longer than 3 months’ duration, a pain-related
consultation with the general practitioner (GP) in the
past 6 months, significant pain-related distress and
disability, consistent analgesic medications use, ability
to communicate in English, and age 18 years or older.
Those needing further medical tests or procedures, or
with conditions expected by the GP to interfere with
participation in the treatment, were excluded.
Potential participants meeting eligibility criteria were
sent an invitation letter, trial information sheet, consent
form, and screening questionnaire by their GPs
(N = 481). Participants who wished to take part re-
turned their signed consent forms and the screening
questionnaire to the research team by post and were
screened for eligibility (n = 102). Twenty-nine potential
participants were excluded at this stage, 22 for not
meeting criteria. Seven did not provide consent.
Seventy-three potential participants were randomized
to ACT (n = 37) or treatment as usual (n = 36). A consort
diagram is included in Fig 1.
Part of the screening process was based on the
disability rating portion of the chronic pain grading
questionnaire by Von Korff and colleagues.28 Eligible
participants needed to rate the level of interference
with their daily activities from pain a 4 or higher on a
scale from 0 = no interference to 10 = unable to carry
on any activities.Participants
The 73 participants randomized ranged from 23 to
86 years old (mean = 58.0, standard deviation
[SD] = 12.8 years), and 27.6% were 65 or older. Most
were women (68.5%) and white British (97.3%). Most
were married or living with a partner (65.7%); 12.3%
were unmarried, 11.0% divorced, 11.0% widowed.
They had completed a mean of 12.4 years of education
(SD = 4.2). The median pain duration was 10.0 years,
Figure 1. CONSORT flow diagram. *One participant in the TAU condition was uncontactable at posttreatment but contactable at
follow-up.
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included low back (37.0%); lower extremity (23.3%);
neck (15.1%); all over (13.7%); or other (10.9%). Partic-
ipants reported wide-ranging and mostly multiple pain-
related diagnoses. The most frequently mentioned
diagnosis was fibromyalgia (32.0%). Only 9.6% were
working full time outside the home. The largest propor-
tion of participants (31.0%) was not working because of
pain, and another 8.2% were working part time
because of pain. The remaining participants were
retired (27.4%); working as homemakers (16.4%); or
other (7.4%). At the initial screening phase, all partici-
pants completed a measure of medical comorbidities,
including 13 health conditions.25 Excluding back pain
from the list, 80.9% of participants reported at least 1
of these; 38.2% reported 2 or more; and 17.6% reported
3 or more. The most commonly reported conditions
included osteoarthritis (30.6%); depression (40.3%);
and hypertension (30.6%).Treatment Outcome and Process
Measures
The baseline, posttreatment, and follow-up measures
included the key domains of patient functioning
deemed appropriate for chronic pain treatment trials,26are well validated and standardized, and are frequently
used in other treatment studies.3 All measures were
administered and returned through the mail. Partici-
pants who did not initially return completed measures
were contacted once by mail and once by telephone to
encourage them to provide their data.
Primary clinical outcome measures included the
disability score from the Roland and Morris Disability
Questionnaire,24 depression severity from the Patient
Health Questionnaire–9,13 the physical functioning score
of theShort FormHealthSurvey (SF-36),33 anda0 to10nu-
merical rating of average pain intensity in the past week.
Secondary outcome measures included the emotional
functioning score from the SF-36; a patient global
impression of change (PGIC) score, a 7-point numerical
rating from 1 = very much improved to 7 = very much
worse5; and a question about changes in medication,
administered at posttreatment and follow-up only.
Health care visits for pain were also tracked through pa-
tient report, including GP visits, other visits to physicians,
and accident and emergency visits during the previous
3-month period. These items were administered before
treatment and at follow-up only.
Treatment process measures included a measure of pain
acceptance, the20-itemChronicPainAcceptanceQuestion-
naire,19 and a measure of general psychological
McCracken, Sato, and Taylor The Journal of Pain 1401acceptance, the 7-item Acceptance Action Questionnaire
II.1 The Chronic Pain Acceptance Questionnaire assesses
the capacity to engage in activities that include pain
without struggling with the pain. The Acceptance Action
Questionnaire II assesses processes of avoidance or being
blocked in functioning fromunwantedpsychological expe-
riences. When the items are reversed for scoring, they are
considered a reflection of general psychological accep-
tance.
Treatment
The group treatment program was an adaptation of
ACT principles and treatment methods for chronic
pain.7,15 The format, setting, and scheduling were
designed with local input from people with chronic
pain, from GPs and practice nurses, and from health
care commissioners, based on group discussion and a
combination of qualitative and quantitative analyses.32
The treatment includes a combinationofmethods topro-
mote psychological flexibility, including acceptance,
cognitive defusion, and values-based and committed ac-
tion. It emphasizes experience-based methods, meta-
phor, and exposure and de-emphasizes lecturing and
information-giving. Before the start of treatment, all par-
ticipants were telephoned by the treatment provider for
a very brief introduction and to begin to build some
rapport. Treatmentwas provided by 1 of 2 trained clinical
psychologists (L.M.M. and another), eachwithmore than
5 years of experience in treatment for chronic pain and
ACT. The format of treatment included 4 sessions, each
4 hours long, delivered 3 sessions one week and 1 session
a week later. The content of the treatment was designed
so that all of the primary treatment processes were intro-
ducedduring thefirst 3 sessions and session4was focused
on review and further enhancing the processes. Hence,
any participant attending at least 3 sessions was consid-
ered to have had exposure to all of the key processes.
The actual allocated group sizes at the 3 separate loca-
tions were the treatment was provided were 12, 12, and
13 participants. All sessions were conducted during
afternoonhours inGPpractices thatwere local to thepar-
ticipants. Treatment consistency and fidelity were main-
tained by use of a treatment manual, and all sessions
were audiotaped for later analysis (not reported here).
Treatment as Usual
Participants in the control arm were asked to follow
their usual treatments, including any new treatments
their GP or their other doctors might wish, during their
time in the study. Medication changes and medical visits
were then assessed at follow-up.
Analyses
Initial data analyses examined the participants in the 2
treatment conditions for baseline differences on back-
ground, treatment outcome, and treatment process vari-
ables. Then a series of analyses of covariance were
calculated, with the outcome and process variables at
posttreatment and follow-up as the dependent variables
and the baseline values as covariates. To assess whetherthere was some influence tied to the 3 varying locations
where recruitment and treatment were done, the loca-
tion of treatment (and therefore treatment groups)
was included as a factor to test whether there was such
an effect in the data. Following the significance tests,
for each of the mean comparisons at posttreatment
and follow-up, between-group effect sizes, Cohen’s d,
were calculated based on posttreatment and follow-up
means and pooled SDs. Group outcome differences in
the categorical PGIC and medication use variables were
examined with chi-square. The clinical outcome and pro-
cess measures were analyzed in 3 separate ways. First, all
available datawere submitted to the between-group an-
alyses, regardless of number of treatment sessions at-
tended. Next, an intention-to-treat (ITT) approach to
these same analyses was usedwith imputation ofmissing
data by last value carried forward. Finally, only those
who were regarded as receiving a full treatment experi-
ence were compared, again, to the control condition. All
significance tests were 2-tailed and alpha was set at
P < .05, given the pilot nature of this project.Results
Attendance and Data Adherence
Thirty-three (89.2%) of the 37 participants allocated to
the ACTcondition attended at least 1 session. Those who
did not attend treatment were unable to do so because
of illness (n = 2); another obligation (n = 1); or unknown
(n = 1). Twenty-seven participants (72.9%) attended 3 or
4 sessions andwere regarded as having a complete treat-
ment experience. Eighteen participants (48.6% of those
allocated to ACT) attended all 4 sessions of ACT. Thirty-
one (83.8% of the 37 participants allocated to ACT)
provided data at posttreatment, and 28 (75.7% of those
allocated) provided data at follow-up. In the TAU condi-
tion, 27 participants (75.0% of those allocated to TAU)
provided data conjointly with the completion of the
ACT treatment, and 28 (77.7%) provided data at the
3-month follow-up.
Preliminary Analyses
Comparisons using independent groups t-tests of
those who provided outcome data showed that the
ACTand TAU conditions did not differ on age, education,
duration of pain, number of comorbid medical condi-
tions, number of physicians seen in the past due to their
pain, or number of times they had seen their GP for pain
in the past 3 months, as assessed at baseline. They also
did not differ on baseline disability, depression, physical
or emotional functioning from the SF-36, acceptance of
pain, or psychological acceptance, all P > .05.
Analyses of the group and location effect, across the 14
posttreatment and follow-up analyses involving mean
comparisons, revealed 2 significant interactions of the
treatment condition effect and this location effect. One
of these involved immediate posttreatment disability,
F(2, 50) = 3.57, P = .036, and the other involved depres-
sion at follow-up, F(2, 48) = 3.31, P = .045. In the first
case, inspection of the data showed that 1 of the
1402 The Journal of Pain ACT for Chronic Pain in General Practicelocations yielded both a relatively high disability score in
the TAU group and a relatively low score for the ACT
group at posttreatment. The direction of differences be-
tween the TAU versus ACT conditions did not differ
across locations, nor did themagnitude of posttreatment
disability scores across the 3 ACT groups, F(2, 28) = 1.71,
P = .20. An analogous situation was observed for the
depression result at follow-up but for a separate
group/location. Once again, no difference between the
ACT groups on depression at follow-up was observed,
F(2, 28) = .03, P = .97. Because these were unsystematic,
minority issues, and possibly spurious, it was elected to
conduct all subsequent analyses with the combined
ACT treatment group data.
Posttreatment Outcome Results
Table 1 includes means, SDs, analysis of covariance re-
sults, and effect sizes from posttreatment and follow-
up. Immediately post treatment, there were significant
group differences in favor of ACT for depression but no
significant changes for disability, physical functioning as
measuredby the SF-36, or pain. The effect sizes for depres-
sion was small, d = .46. In terms of secondary outcomes,
there was a significant posttreatment effect on PGIC,
with 53.3% of those in the ACT condition reporting over-
all improvement whereas in the TAU group the number
was 25.0%. There was no significant group differenceTable 1. Results Including All Those Providing Data
Follow-Up)
GROUP
MEAN (SD)
PRETREATMENT POSTTREATMENT FOLLO
Primary outcomes measures
Disability ACT 12.23 (4.53) 9.96 (4.85) 10.82
TAU 12.19 (4.84) 12.58 (6.02) 14.14
Depression ACT 11.58 (5.81) 9.53 (6.84) 9.95
TAU 12.44 (7.03) 13.04 (8.31) 14.08
Physical functioning ACT 30.35 (22.16) 31.13 (19.99) 31.51
TAU 29.18 (27.76) 27.32 (24.44) 22.61
Pain ACT 6.51 (1.92) 6.45 (1.92) 6.54
TAU 7.00 (1.64) 7.27 (1.73) 7.19
Treatment process measures
Pain acceptance ACT 54.87 (14.39) 64.97 (15.13) 71.11
TAU 56.92 (16.14) 54.92 (17.04) 64.89
Psychological acceptance ACT 23.83 (10.77) 23.60 (11.16) 23.19
TAU 24.72 (9.81) 25.77 (10.75) 25.55
Secondary outcomes
Emotional functioning ACT 52.02 (25.43) 65.55 (16.93) 64.21
TAU 50.15 (23.71) 50.50 (24.56) 49.71
Percentage Improve
Patient rating of change ACT 53.33 51
TAU 25.00 26
Medication reduction ACT 10.3 15
TAU 4.2 18
Abbreviation: ANCOVA, analysis of covariance.
NOTE. Disability was measured with the Roland and Morris Disability Questionnaire,
average pain in the past week, physical and emotional functioning with the SF-36, p
acceptance with the Acceptance and Action Questionnaire–II, rating of change with
with a single self-report item asking whethermedication was increased, decreased, or
from 28 to 31 and in the control condition from 26 to 27, including both posttreatm
*P < .05. d > .20, small; >.50, medium; >.80, large.on emotional functioning from the SF-36. Most patients’
pain medication stayed the same in both groups during
the treatment interval. One participant in the TAU condi-
tion and 3 in the ACT condition reported a decrease in
their medication. Six participants in the TAU condition
and 4 in the ACT condition reported increases. The differ-
ence between groups was not significant.Follow-Up Outcome Results
At the 3-month follow-up, there were significant
treatment group differences in outcome in favor of
ACT for disability and depression. There were no signifi-
cant group differences for the measures of physical func-
tioning or pain. The effects at follow-up for disability,
d = .59, and depression, d = .58, were medium. There re-
mained roughly twice as many participants in the ACT
condition compared to the TAU condition who rated
themselves as improved at follow-up; however, this ef-
fect marginally missed statistical significance, P = .064.
Once again, as at posttreatment, there were no signifi-
cant group differences in the emotional functioning
score from the SF-36 or in pain medication changes.Treatment Process Results
Contrary to predictions, there were no significant
group differences in either acceptance of pain or general(n = 58 at Posttreatment, n = 54 at 3-Month
BETWEEN-GROUP ANCOVA: F BETWEEN-GROUP EFFECT SIZE: d
W-UP POSTTREATMENT FOLLOW-UP POSTTREATMENT FOLLOW-UP
(5.55) 3.16 6.10* .32 .59
(5.19)
(7.01) 5.60* 4.45* .46 .58
(6.68)
(23.28) <1 1.60 .17 .39
(21.19)
(2.10) 1.41 <1 .44 .32
(2.03)
(8.86) 3.60 5.83* .26 .64
(11.72)
(12.00) <1 <1 .20 .22
(9.55)
(21.84) 3.70 1.08 .68 .20
(22.11)
d c2
.90 4.43* 3.43
.08
.38 <1 <1
.18
depression with the Patient Health Questionnaire–9, pain with a 0 to 10 scale of
ain acceptance with the Chronic Pain Acceptance Questionnaire, psychological
the 1 to 7 Patient Global Impression of Change scale, and medication reduction
stayed the same. Because ofmissing data, the actual n in the ACTcondition varies
ent and follow-up time points.
McCracken, Sato, and Taylor The Journal of Pain 1403psychological acceptance immediately at the completion
of the 2-week ACT treatment phase. The difference in
acceptance of pain marginally missed significance,
P = .063. At follow-up, there remained no significant
group difference for general psychological acceptance;
however, the group difference in acceptance of pain at
this point did reach significance and the effect size was
medium, d = .64.
ITT Analyses
Using the last-value-carried-forward method for
imputing missing values, ITT analyses on all of those ran-
domized to either ACTor TAU showed a significant effect
immediately post treatment for disability, F(1, 70) = 4.43,
P < .05, d = .36; depression, F(1, 70) = 5.91, P < .05, d = .46;
andmarginally significant effects for acceptance of pain,
F(1, 70) = 3.91, P = .05, d = .23; and emotional func-
tioning, F(1, 70) = 3.93, P = .05, d = .69. There were no sig-
nificant effects immediately following treatment for
physical functioning, pain, or general psychological
acceptance. At follow-up, there was a marginal effect
for disability, F(1, 70) = 3.38. P = .07, d = .37, but no signif-
icant effects for depression, physical functioning, pain,
acceptance of pain, general acceptance, or emotional
functioning.
Treatment Completer Analyses
There were 27 participants of those who were allo-
cated to ACT who attended 3 or 4 sessions, 6 who at-
tended 1 or 2 sessions, and 4 who attended none.
Three sessions was regarded as the minimum number
for being regarded as having completed treatment.
Based on analysis of covariance, comparing these treat-
ment completers with the TAU condition, there were sig-
nificant effects in favor of ACT immediately post
treatment for disability, F(1, 49) = 8.39, P < .01, d = .45;
depression, F(1, 49) = 8.72, P < .01, d = .53; acceptance
of pain, F(1, 49) = 4.59, P < .05, d = .51; and emotional
functioning, F(1, 49) = 4.07, P < .05, d = .71. There were
no significant effects immediately post treatment for
physical functioning, pain, or general acceptance. At
follow-up, there were significant effects for disability,
F(1, 51) = 5.43, P < .05, d = .55; depression,
F(1, 50) = 5.82, P < .05, d = .59; and acceptance of pain,
F(1, 48) = 4.87, P < .05, d = .59. There were no significant
effects at follow-up for physical functioning, pain, gen-
eral acceptance, or emotional functioning.
In the completer analyses, as in the analyses of all those
providing data, global ratings of improvement immedi-
ately following treatment again significantly favored
the ACT condition, c2(1, n = 48) = 4.87, P < .05. Global
ratings of improvement at follow-up did not show a sig-
nificant difference, P = .067.
Additional Post Hoc Analyses
In general, there was not a high rate of health care use
in the treatment groups during 3-month period before
the start of treatment and at follow-up. The modal num-
ber of GP visits was 1 and the modal number of other
doctor and accident and emergency visits was zero inboth groups at both time points. At follow-up, there
were just 20.4% of participants who saw their GP more
than 2 times. Eight of these 11 people (72.5%) reported
3 or 4 visits, 1 reported 5 visits, and 2 reported weekly
visits, a pattern that had carried on from pretreatment.
Therewere no significant follow-up differences between
the treatment conditions in GP visits, other doctor visits,
accident and emergency visits, or total visits during the
3-month follow-up interval, all t < 1.67, all P > .10.Discussion
The current study was developed as a pilot RCT of ACT
in comparison to treatment as usual for chronic pain in a
general practice setting in the United Kingdom. The
setting, recruitment strategy, and the brief treatment
format had not been previously tested and the present
study was designed to see if an RCT could be conducted
with these elements. In this trial, we demonstrated suc-
cessful recruitment of the targeted number of partici-
pants, greater than 60, in a short period of 2 months at
each of 3 locations; 73% in the ACT condition were
regarded as having received the complete treatment,
and more than 75% of the total sample randomized
were retained at follow-up.
Power calculations were not done nor were formal
predictions of significant treatment effects made during
the design of this study. With this proviso in mind the
ACTcondition did produce a number of significant treat-
ment effects compared to the TAU condition, on depres-
sion and patient-rated improvement at posttreatment
and on disability, depression, and pain acceptance at
the 3-month follow-up. Effect sizes for the significant ef-
fects were small for depression immediately post treat-
ment, and medium for disability, depression, and
acceptance of pain at follow-up.
Analyses done on an ITT basis or focused only on those
who were regarded as completing treatment provide
distinctly differing views of the trial results. The ITT ana-
lyses showed significant effects in favor of ACT for
disability and depression but only nonsignificant mar-
ginal effects for acceptance of pain and emotional func-
tioning. Only a marginal nonsignificant effect for
disability remained at follow-up. Analyses excluding par-
ticipantswhomissed 2 ormore of the 4 sessions, so-called
completer analyses, showed more positive results,
including significantly better results for the ACT condi-
tion in comparison to the TAU condition on disability,
depression, pain acceptance, and emotional functioning
at posttreatment, and disability, depression, and pain
acceptance at follow-up. Significant between-group ef-
fect sizes were small to medium at posttreatment and
medium at follow-up. It should be clarified that the sam-
ple size of this RCT is small compared to trials designed to
produce more definitive results.14 These results ought to
be seen as preliminary. The positive results from the
completer analyses compared to ITT particularly call for
further investigation of the variables that identify who
completes and who does not complete treatment, how
to improve engagement, and whether it is possible to
identify those who achieve poor results regardless.
1404 The Journal of Pain ACT for Chronic Pain in General PracticeThere are anumberof other preliminary RCTs ofACT for
chronic pain,2,27,35,36 and at least 1 larger trial comparing
ACT to more traditional CBT (N = 114).34 There are also
nonrandomized, partly controlled, or pilot studies,10,20,31
a reanalysis of treatment outcome focused on older
adults,17 and several effectiveness studies,16,29 including
1 showing good outcomes at 3 years posttreatment.30
The present study is consistent with the previous ones in
providing support for ACT and in providing a basis for
more ambitious or more focused studies. It differed from
the earlier studies in that it was conducted exclusively
within primary care in the United Kingdom, with very lib-
eral inclusion criteria, with no face-to-face assessment or
screening, and unlike some of the earlier RCTs it included
group delivery. It was also significantly briefer in the num-
ber of sessions and in total treatment hours compared
with some previous group-based treatments, particularly
those conducted in the United Kingdom.16,20
It may appear unnecessary to conduct or present more
preliminary trials of ACT. However, the planning and
application for funding the current study began in
2008, a time when there were significantly fewer pub-
lishes studies. Certainly the unique features in the design
of the current treatment represent, including its base in
UK primary care, its 4-session format, and its minimal
screening, provide a way to examine the robustness
and generality of the treatment model.
There are some inconsistencies in our current results
that may provide a basis for improvement in later trials.
Unexpectedly, participants in the TAU condition demon-
strated increases in disability and depression, especially
at follow-up. These changes contribute to the observed
between-group effects on these outcomes. Perhaps
even more unexpectedly, they also demonstrated a
remarkable increase in acceptance of pain, a change
that reduced the between-group effect. The posttreat-
ment effect on acceptance of pain was small. This is
inconsistent with our previous studies, where effects on
acceptance of pain were large and among the largest
achieved in comparison to other outcome and process
variables.16,29 Likewise, we produced only small
nonsignificant effects on our measure of general
psychological acceptance, among the smallest of all
those observed, and small or inconsistent effects on the
physical and emotional functioning scales of the SF-36.
In future studies, with treatment formats similar to the
one used here, treatment providers may need to inten-
sify the methods applied to pain-related and psycholog-
ical acceptance or devote more time to these.
The sample of participants encountered in this study
was more chronic, more complex, and more diverse
than expected. There were highly disabled participants
who had failed previous psychological treatments with
a higher intensity than the treatment provided here. It
is clear that the SF-36 scales in particular produced highly
variable scores. There were some participants with
extremely limited mobility—2 participants attended in
wheelchairs. In the future, it may improve the outcome
of trials of a similar treatment format to narrow the
range of disability among the participants, add a physical
rehabilitation piece to the psychology treatmentmethods for those with higher physical disability, and
perhaps to screen out those who had already failed
higher-intensity treatments of a similar type. A screening
visit with a treatment provider, rather than solely paper-
based screening as done here, could certainly help to
screen out some cases where there is a high likelihood
that the treatment will not meet their needs. This is
normal in actual clinical practice. Finally, there were
engagement challenges, particularly in the 27% of par-
ticipants in the ACT condition who did not participate
in a full treatment experience. This trial was not re-
sourced to address engagement as is sometimes done
in specialty treatment centers, such as with additional
one-to-one sessionswith some participants. On the other
hand, this treatment was designed for high accessibility
and for efficient delivery, and this was achieved, albeit
with the result that some individuals may have received
less than optimal results.
In previous results from this same sample, it was shown
that participants in the ACT groups found the treatment
credible and found participating in the study accept-
able.18 It was also found that some participants experi-
enced greater pain or fatigue, or found the sessions
too lengthy. Even though this was not the majority, it
was nonetheless a significant minority. This is somewhat
a conundrum as ACT actually operates by including un-
wanted psychological experiences in treatment delivery
so that the ways that these can create barriers to daily
functioning can be examined directly and so that new
patterns of behavior can be shaped and rehearsed in
the context of treatment. Certainly the group delivery
mode and the limited one-to-one relationship between
the therapist and each participant place some limits on
how a treatment provider can reverse avoidance pat-
terns that occur in treatment sessions, and seek to loosen
the grip of thoughts and beliefs that participants hold
tightly. Finally, even though we attempted to ease the
burden of participation by designing a 4-session treat-
ment, the 4-hour session length and the total treatment
time remain a considerable burden and certainly will not
suit some people’s circumstances. These are challenges
for continuing treatment development.
The present study obviously has a number of limita-
tions both as a pilot and especially as a test of ACT. First,
it is no more than a pilot for a pragmatic trial, as there
was no active treatment comparison condition. This
type of design does not allow specific statements about
the efficacy of ACT. The region of the country and the
specific GP practices involved represent a selected sam-
ple, and it is not clear that similar results will be obtained
in other regions and other practices. The clinical
outcome results for disability and depression were not
echoed in effects on physical and emotional functioning.
Even given the limited statistical power here, this means
that either the treatment is failing in some specific way
or the SF-36 is not sensitive to specific treatment results.
We did learn that some of the participants struggled
with the wording in some of the items of the SF-36,
particularly the distance implied by a ‘‘block,’’ a concept
not commonly used in the United Kingdom, and the
notion of ‘‘full of pep.’’ In the future, a change in this
McCracken, Sato, and Taylor The Journal of Pain 1405measure or in the treatment is advisable. Finally, as a
small RCT without registered trial unit support, it was
not powered for a definitive result and certainly there
are potential sources of bias that are uncontrolled.
Although data were gathered and entered blind and an-
alyses were supervised by a statistician (G.J.T.), they were
not all conducted blind to treatment condition, for
example.
In summary, further larger-scale trials of ACT for
chronic pain, such as in primary care and in the United
Kingdom, appear feasible and are recommended, with
a few adjustments from the methods used here. Signifi-
cant treatment effects for disability, depression, and
pain acceptance may be achievable, including perhaps
medium-sized effects after a short follow-up interval of
3 months. We hypothesize that a number of factors
may have reduced treatment impact, and perhaps
greater attention to these can be incorporated in future
trials. It seems possible, based on comparisons with pre-
vious results, that 1 or more of the following modifica-tions could improve outcomes: intensifying the
methods to produce results on acceptance, especially
general psychological acceptance; recruiting a more ho-
mogeneous sample in their current functioning;
excluding those who failed previous treatments;
including a face-to-face assessment prior to the start of
treatment; including a physical exercise component;
and/or allowing one-to-one sessions for patients with
engagement difficulties.Acknowledgments
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